To develop these standards, the research team employed a Delphi consensus study, a structured communication technique used to reach a high-level agreement among a panel of experts. The study brought together 89 leading experts from 17 different countries, facilitating a multi-round debate to distill the most important factors in a psychedelic experience. The resulting 30-item checklist covers a wide range of psychosocial factors, ensuring that researchers everywhere are looking at the same variables when they report their findings.
Why guidelines matter
The practical implications of these guidelines extend far beyond the walls of academic laboratories. The absence of such standards has already had tangible consequences for the future of mental health care. A prominent example cited by the researchers is the recent decision by the U.S. Food and Drug Administration to reject a proposal for MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Despite years of advocacy and positive anecdotal reports, the FDA pointed to inconsistent reporting across various trials as a primary reason for the rejection. Without a standardized way to report on the therapeutic environment and the mindset of the participants, the agency found it difficult to validate the data presented.
Pronovost-Morgan explained that this lack of standards creates a bottleneck in the drug development pipeline. If the scientific community cannot agree on how to measure the "setting" of a trial, it cannot provide the level of evidence required for federal approval. The ReSPCT guidelines are intended to bridge this gap, offering a standard framework that makes trial outcomes more consistent, comparable, and ultimately, more reliable for regulators.
Leor Roseman, a co-senior author from the University of Exeter, emphasized that these guidelines are essential for distinguishing psychedelics from other classes of psychiatric medications. "Having clear guidelines for contextual considerations is essential to understand the effects of psychedelics and how they work differently from other psychiatric medications," Roseman said. "Our guidelines will also help in replicating results and understanding the true therapeutic potential of psychedelics."
Unlike standard antidepressants, which are often taken daily to manage symptoms over a long period, psychedelic-assisted therapy typically involves a limited number of high-dose sessions integrated with intensive psychotherapy. In this model, the "drug" acts more like a catalyst for a psychological process rather than a standalone cure. Therefore, the conditions under which that catalyst is introduced—the comfort of the room, the trust between the patient and the clinician, and even the selection of music—become integral to the treatment itself.
The urgency of this work is underscored by the current global mental health crisis. With rates of PTSD, depression, and anxiety reaching record highs, many patients find that existing treatments are insufficient. Traditional Selective Serotonin Reuptake Inhibitors (SSRIs) and talk therapy do not work for everyone, leaving millions of people searching for alternatives.
